Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer.
Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. Papadaki C, et al. Among authors: tryfonidis k. Br J Cancer. 2011 Jan 18;104(2):316-23. doi: 10.1038/sj.bjc.6606027. Epub 2010 Dec 14. Br J Cancer. 2011. PMID: 21157449 Free PMC article.
A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N, Kouroussis Ch, Papakotoulas P, Kalbakis K, Tryfonidis K, Vardakis N, Poppis E, Georgoulias V, Mavroudis D. Karachaliou N, et al. Among authors: tryfonidis k. Cancer Chemother Pharmacol. 2012 May;69(5):1345-52. doi: 10.1007/s00280-012-1824-z. Epub 2012 Feb 17. Cancer Chemother Pharmacol. 2012. PMID: 22349809 Clinical Trial.
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N, Ziras N, Syrigos K, Tryfonidis K, Papadimitraki E, Kontopodis E, Bozionelou V, Kalykaki A, Georgoulias V, Mavroudis D. Karachaliou N, et al. Among authors: tryfonidis k. Cancer Chemother Pharmacol. 2012 Jul;70(1):169-76. doi: 10.1007/s00280-012-1901-3. Epub 2012 Jun 6. Cancer Chemother Pharmacol. 2012. PMID: 22669571 Clinical Trial.
A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer.
Tryfonidis K, Boukovinas I, Xenidis N, Christophyllakis C, Papakotoulas P, Politaki E, Malamos N, Polyzos A, Kakolyris S, Georgoulias V, Mavroudis D; Hellenic Oncology Research Group. Tryfonidis K, et al. Breast. 2013 Dec;22(6):1171-7. doi: 10.1016/j.breast.2013.08.017. Epub 2013 Oct 1. Breast. 2013. PMID: 24091128 Free article. Clinical Trial.
Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial.
Aalders KC, Touati N, Tryfonidis K, Annonay M, Litiere S, Bergh J, Bodmer A, Cameron DA, Bonnefoi HR; EORTC 10994/BIG 1-00 Study Investigators. Aalders KC, et al. Among authors: tryfonidis k. Breast Cancer Res Treat. 2018 Jun;169(3):497-505. doi: 10.1007/s10549-018-4698-x. Epub 2018 Feb 12. Breast Cancer Res Treat. 2018. PMID: 29435853
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.
Tryfonidis K, Papadaki C, Assele S, Lagoudaki E, Menis J, Koutsopoulos A, Trypaki M, Tsakalaki E, Sfakianaki M, Hasan B, Stathopoulos E, Georgoulias V, Souglakos J. Tryfonidis K, et al. Pharmacogenomics J. 2019 Feb;19(1):15-24. doi: 10.1038/s41397-018-0013-9. Epub 2018 Feb 22. Pharmacogenomics J. 2019. PMID: 29472587
Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.
Ignatiadis M, Rack B, Rothé F, Riethdorf S, Decraene C, Bonnefoi H, Dittrich C, Messina C, Beauvois M, Trapp E, Goulioti T, Tryfonidis K, Pantel K, Repollet M, Janni W, Piccart M, Sotiriou C, Litiere S, Pierga JY. Ignatiadis M, et al. Among authors: tryfonidis k. Eur J Cancer. 2016 Aug;63:97-104. doi: 10.1016/j.ejca.2016.04.024. Epub 2016 Jun 10. Eur J Cancer. 2016. PMID: 27289552 Review.
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, Dijkstra NH, Schröder CP, van Asperen CJ, Linderholm B, Benstead K, Foekens R, Martens JWM, Bartlett JMS, van Deurzen CHM. Vermeulen MA, et al. Among authors: tryfonidis k. Eur J Cancer. 2017 Sep;82:219-227. doi: 10.1016/j.ejca.2017.01.034. Epub 2017 Mar 11. Eur J Cancer. 2017. PMID: 28292559
Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study.
Tryfonidis K, Marreaud S, Khaled H, De Valk B, Vermorken J, Welnicka-Jaskiewicz M, Aalders K, Bartlett JMS, Biganzoli L, Bogaerts J, Cameron D; EORTC- Breast Cancer Group. Tryfonidis K, et al. Breast Cancer Res Treat. 2017 Jun;163(3):507-515. doi: 10.1007/s10549-017-4203-y. Epub 2017 Mar 21. Breast Cancer Res Treat. 2017. PMID: 28324265 Clinical Trial.
49 results